

Stockholm, December 22, 2008

New CEO for SCN

On December 19, 2008, the Board of Scandinavian Clinical Nutrition AB (SCN) elected a new CEO for the company. Carsten Waern, Member of the Board, takes over after Thomas Christensen, who is leaving the company due to a new assignment.

"Thomas Christensen has done a great job as CEO of SCN, and we are very grateful for the hard work he has led with building up a well-functioning working structure and making SCN what it is today. We wish him the best of luck in the future", says Ulf Söderberg, Chairman of the Board of SCN.

The new CEO, Carsten Waern, is currently a Board Member of SCN, but he has previously been both Chairman of the Board of the company, and CEO of SCN Denmark A/S, the Danish company SCN acquired in 2007. He has extensive experience from the nutrition industry, and has both connections and knowledge which will be important for SCN as the company continues to expand its business.

Thomas Christensen also resigns from his assignment as Board Member in SCN with immediate effect.

For more information, please contact:

Carsten Waern, CEO, cw@scnutrition.com, +45 2090 8888

Ulf Söderberg, Chairman of the Board, +46 708 13 22 81

Scandinavian Clinical Nutrition AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker "SCN" on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se). For more information, please visit www.scnutrition.com.